Marksans Pharma smashes records: 18% revenue surge and massive profit boost in Q1 FY25
Marksans Pharma Ltd. (NSE: MARKSANS; BSE Code: 524404) has unveiled its financial results for the quarter ending June 30, 2024, highlighting a robust start to ... Read More
Marksans Pharma bags FDA approval for Mucinex bioequivalent tablets
Indian pharmaceutical powerhouse, Marksans Pharma has achieved a significant milestone, securing the coveted US Food and Drug Administration (FDA) nod for its Abbreviated New Drug ... Read More
Marksans Pharma gets FDA final approval for Famotidine Tablets
Marksans Pharma said that it has been granted final approval for the over-the-counter (OTC) use of Famotidine Tablets USP, 10 mg and 20 mg from ... Read More